tailieunhanh - Báo cáo y học: "Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. | Chevalier et al. Arthritis Research Therapy 2011 13 124 http content 13 4 124 REVIEW Desperately looking for the right target in osteoarthritis the anti-IL-1 strategy Xavier Chevalier1 Thierry Conrozier2 and Pascal Richette3 See related research by Cohen etal. http content 13 4 R125 Abstract Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen and colleagues report a randomised placebo-controlled multiple-dose trial using a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive results in terms of evolution of pain for up to 12 weeks in line with the former trials using intraarticular injections of IL-1 receptor antagonist. A trend was observed however in a subgroup of patients with high level of pain at baseline. Although these data may suggest cessation of IL-1 therapy in osteoarthritis other methods such as limited intraarticular anti-IL-1 delivery should still be considered. One of the most exciting challenges in rheumatology for the future is to find a therapeutic target for osteoarthritis OA 1 . Indeed clinicians and our patients are still waiting for a new drug that exhibits an analgesic effect and structure-modulating properties. OA is characterised by an imbalance between catabolic and anabolic responses of stimulated chondrocytes driven locally by a soup of cytokines where IL-1p is regarded as the chief orchestrator. On the one hand IL-1 can induce the production of enzymes prostanoids nitric oxide and free radicals on the other hand IL-1 can block the production of collagen type 2 and proteoglycans 2 3 . IL-1 is also involved in the transmission of pain 4 . Considering all these factors targeting IL-1 in OA seems a logical approach to slow down the disease progression. In different animal models Martel-Pelletier and colleagues were the first to use IL-1 receptor antagonist IL-1ra injected intraarticularly - either directly or Correspondence .